CLE for Assessment of Neoplasia After Mucosal Ablation or Resection of Gastrointestinal Neoplasia

NCT ID: NCT01032044

Last Updated: 2016-04-22

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

164 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-02-28

Study Completion Date

2011-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study focuses on demonstrating the value of probe-based Confocal Laser Endomicroscopy (pCLE) in guiding endoscopic therapeutic procedures in Barrett's Esophagus (BE).

It is a randomized controlled outcomes study including patients already treated for Barrett's Esophagus lesion(s) and undergoing high definition white light endoscopy follow up procedure, with or without pCLE (2 arms will be considered in this study). The procedures will be carried out per standards of practice with appropriately trained physicians.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

It is a randomized controlled outcomes study including patients already treated for Barrett's Esophagus lesion(s) and undergoing high definition white light endoscopy follow up procedure, with or without pCLE guided evaluation (2 arms will be considered in this study). The procedures will be carried out per standards of practice with appropriately trained physicians.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Barrett Syndrome Barrett's Syndrome Barrett's Esophagus Barrett Esophagus Adenocarcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Standard endoscopic evaluation

Standard high-definition white light endoscopy guided evaluation

Group Type ACTIVE_COMPARATOR

Standard endoscopic evaluation

Intervention Type DEVICE

Treatment modalities can include endoscopic mucosal resection, radio-frequency ablation or photodynamic therapy

pCLE-guided evaluation

Endoscopic evaluation of BE guided by probe-based Confocal Laser Endomicroscopy (pCLE guided evaluation)

Group Type EXPERIMENTAL

pCLE guided evaluation

Intervention Type DEVICE

Treatment modalities include endoscopic mucosal resection, radio-frequency ablation, or photodynamic therapy. probe-based Confocal Laser Endomicroscopy is used to decide on re-treatment or not, and to guide and evaluate the treatment during the same endoscopic procedure.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Standard endoscopic evaluation

Treatment modalities can include endoscopic mucosal resection, radio-frequency ablation or photodynamic therapy

Intervention Type DEVICE

pCLE guided evaluation

Treatment modalities include endoscopic mucosal resection, radio-frequency ablation, or photodynamic therapy. probe-based Confocal Laser Endomicroscopy is used to decide on re-treatment or not, and to guide and evaluate the treatment during the same endoscopic procedure.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with BE with Intestinal Metaplasia, Low Grade-IntraEpithelial Neoplasia/High Grade-IntraEpithelial Neoplasia as the original indication for ablative treatment.
* Undergoing any type of endoscopic BE ablation treatment
* \<2cm of circumferential BE and \<5 total islands of BE on prior to last ablation.
* Age \> 18 years
* Ability to provide written, informed consent

Exclusion Criteria

* Participation in another clinical study
* Circumferential BE
* Complete eradication of BE documented by biopsies
* Inability to obtain biopsies due to anticoagulation, varices, etc.
* Allergy to fluorescein
* Pregnancy
* Renal insufficiency
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Cellvizio Inc.

INDUSTRY

Sponsor Role collaborator

Mauna Kea Technologies

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Michael Wallace, MD

Role: PRINCIPAL_INVESTIGATOR

Mayo Clinic Jacksonville, Florida, United States

Anne Osdoit

Role: STUDY_DIRECTOR

Mauna Kea Technologies, Paris, France

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Mayo Clinic

Jacksonville, Florida, United States

Site Status

University of Chicago Hospital

Chicago, Illinois, United States

Site Status

Veterans Affairs Hospital

Kansas City, Missouri, United States

Site Status

University of Washington Medical Center

Seattle, Washington, United States

Site Status

Centre Hospitalier Universitaire

Nantes, , France

Site Status

University College London Hospital

London, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States France United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Wallace MB, Crook JE, Saunders M, Lovat L, Coron E, Waxman I, Sharma P, Hwang JH, Banks M, DePreville M, Galmiche JP, Konda V, Diehl NN, Wolfsen HC. Multicenter, randomized, controlled trial of confocal laser endomicroscopy assessment of residual metaplasia after mucosal ablation or resection of GI neoplasia in Barrett's esophagus. Gastrointest Endosc. 2012 Sep;76(3):539-47.e1. doi: 10.1016/j.gie.2012.05.004. Epub 2012 Jun 28.

Reference Type DERIVED
PMID: 22749368 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MKT-2009-BE-01

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.